Pearl
Starknet
Quantus
Sui
NEAR Protocol
Pudgy Penguins
Lighter
- AMRS stock fell 82.22% in a week, 91.39% in six months, and 91.50% YTD.
- Amyris filed for Chapter 11 bankruptcy and received a NASDAQ delisting notice.
Amyris Inc. filed for Chapter 11 bankruptcy on August 9, 2023, and received a delisting notice from NASDAQ on August 10, 2023, but AMRS stock gained 107.73%. The biotech company Amyris and its domestic units voluntarily started Chapter 11 bankruptcy proceedings with the United States Bankruptcy Court for the District of Delaware. The filing had a solid argument for restructuring its financials and operations.
Amyris Inc. (AMRS) Stock: Financial Analysis
Amyris is a synthetic biotechnology company with its trademark Lab-to-Market technology platform and clean beauty consumer brands. It has announced moving ahead with operational and financial restructuring, aiming for long-term success. When the news of bankruptcy broke out, the AMRS stock price fell nearly 70%.
Amyris plans to continue operating its consumer brands, vial retail partners, and e-commerce platforms after selling these vertices. The company had already secured a $190 Million commitment for an entity affiliated with their existing lender, Foris Ventures. The new entity would facilitate day-to-day operations.
In the Chapter 11 filing, Amyris’ assets were estimated between $500 Million to $1 Billion, while liabilities were in the range of $1 Billion to $10 Billion. The company reported a net loss of $193.3 Million in Q1 2023, a sharp 80% drop from the net loss of $107.3 Million posted in Q1 2022.
As the stock price was below $1.00 from April to June 2023, it gained a bit and fell below the mark from July 2023, NASDAQ notified Amyris of delisting or failure to satisfy a continued listing rule. Moderna Inc. (NASDAQ: MRNA) gained 1.21% to $101.49.
Amyris Inc. (NASDAQ: AMRS): Technical Analysis
AMRS stock, at press time, is trading at $0.1369 and gained a whopping 107.73%; previous close and open were at $0.0659 & $0.1199, respectively. The 52-week range is from $0.0600 to $10.89, indicating the stock is scraping the bottom. With a volume of 670.80 Million shares, the market cap is $50.569 Million.
The trailing twelve-month (TTM) earnings per share (EPS) is minus $2.01. Analysts placed a 2.17 rating for “hold” and estimated a price target at $3.06 with a staggering upside of $2,133.1%.
Amyris reported previous earnings on May 9, 2023, where the reported revenue of $56.1 Million surpassed the estimated value of $53.045 Million by 5.75%. In comparison, the reported earnings of minus $0.53 per share failed to beat the estimated value of negative $0.332 by 59.80%.
The earnings gained 8.11% compared to the previous quarter, but revenue fell by 2.82%. This mixed earnings report caused the PRU stock price to fall nearly 35% before pulling back.
The subsequent earnings will be released on August 14, 2023, where the market experts predicted the revenue to be around $274.3 Million, while EPS should be at $0.28.
The (TTM) revenue is $268.22 Million, while the growth of year-over-year (YoY) quarterly revenue fell by 2.80%. Amyris’ gross profit (TTM) fell by 97.74 Million, while the net income dropped by 80.18% to negative $193.34 Million. PRU stock fell 82.22% in a week, 87.80% in a month, and 91.50% YTD.
Amyris Inc. (AMRS) Stock: Candle Exploration
The recent pullback of over 100% after the bankruptcy announcement could be due to a short squeeze. It could be good news for investors if the price crosses immediate resistance at $0.3437 and sustains for a considerable time. But the possibility of a bullish momentum or price entering the selling zone is slim.
Descending 200EMA hints at a drop; the relatively flat moving 50EMA also reported a sharp drop, again suggesting a price drop. However, the RSI at 22.25 entered the oversold zone; this condition usually refers to a price jump. If Amyris’ finances get a boost, the stock price could soon cross the $1.00 barrier.
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational purposes only and do not establish financial, investment, or other advice. Investing in or trading crypto assets and stocks comes with a risk of financial loss.
